Overview

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals